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Immunology is rooted in the discoveries of Pasteur and Jenner that 
contact with infectious agents could confer protection. Subsequently, 
attempts to explain this immunity centered upon the humoral factors 
involved until Chase and Landsteiner showed that delayed hypersensi¬ 
tivity could be transferred passively with peritoneal exudate cells. 
With the discovery that the small lymphocyte was involved in delayed 
hypersensitivity reactions, a new era of investigation was inaugurated. 
In the past fifteen years, scientists have distinguished at least 
two types of peripheral lymphocytes - those cells which enter the 
peripheral tissue via the thymus (the T cell), and those cells which 
do not (the bone marrow derived lymphocyte or B cell). These two 
cell populations are indistinguishable by conventional morphological 
techniques, but they are separable functionally. The B cell is the 
precursor of the antibody producing plasma cell and thus is directly 
involved in humoral immunity. The T cell plays a major roll in cellular 
immunity and recent evidence indicates that it also is involved in re¬ 
gulating certain B cell humoral responses. 
Because of its importance in the immune system, the T cell has 
become a subject of intense investigation. It is the purpose of this 
thesis to review the work in this area and to present further evidence 
concerning the role of the T cell in tumor allograft rejection. 

2 
Review of the Literature 
In mammals the thymus consists of a paired endodermal structure 
derived from the third and fourth brachial clefts. It increases in 
size until puberty when it regresses in relation to body development.^ 
Histologically the organ is composed of a distinct medullary and cortical 
2 regions. 
The function of the thymus remained an enigma until it was shown 
that thymectomized neonatal rodents responded poorly to certain antigens, 
3-11 
particularly those stimulating delayed hypersensitivity reactions. 
A marked deficiency of lymphocytes was noted in the peripheral blood, 
lymph nodes, and spleen. The same immunologic and morphologic defi¬ 
ciency was noted when adult mice were thymectomized and given sublethal 
12 
irradiation. This immune deficiency was unchanged following recon- 
13 
stitution with cells from the bone marrow of syngeneic animals. 
However, immunologic competence could be restored by implanting syn¬ 
geneic thymuses.14“17 Szenberg and Warner, and subsequently Cooper, 
showed that in the chicken, thymectomy was associated with an impair¬ 
ment of the capacity to reject skin grafts, but not with defects in 
I O I Q 
antibody production. ’ Thus, the thymus was established as a major 
factor in the development of peripheral lymphoid tissue and in certain 
forms of the immune response. 
Many believed that the thymus exerted its influence by humoral 





this belief. Another line of evidence, however, established that 
cells do pass through the thymus. When thymus tissue bearing a chromo¬ 
some marker (T6) was implanted in thymectomized, tolerant hosts, donor 
no n s 
cells were found in the peripheral lymphoid tissue of the host. “ 0 
The labeled cells localized in specific areas of the peripheral tissue. 
Large numbers were found in the thoracic duct. The cells were present 
in the cortex and paracortical areas of lymph nodes, and in the peri- 
arteriolar lymphocyte sheaths of the spleen. These were the same 
areas previous investigators had noted to be depleted in neonatally 
27—2 8 
thymectomized animals.“ This type of study involves the disruption 
of the donor thymic tissue which might allow these cells to escape, 
thus giving artifactual results. However, another series of experi¬ 
ments in which newborn rodent thymuses were labeled in situ with tri- 
2 9 
tiated thymidine confirmed the results of the T6 investigations. 
The fate of the peripheral thymus-derived lymphocytes was explored 
by Miller and Mitchell. Radioactively tagged T cells were injected 
into heavily irradiated syngeneic hosts with sheep RBC. Some of the 
donor cells in the host spleen responded to the antigenic stimulus 
by forming large, pyroninophilic cells which then gave rise to small 
30-31 
lymphocytes. These small lymphocytes did not produce any de- 
tectable antibody to the sheep RBC and were traced to the paracortical 
areas of lymph nodes and the periarteriolar lymphocyte sheaths in the 
spleens of the host animals. On the basis of this evidence, these 





might be the progeny of thymus cells which had been exposed to antigens 
in the past. 
Our present knowledge of the specific actions of T cells is partly 
derived from studies on in vitro killing of allogeneic cells and from 
the studies of the graft-versus-host (GVH) reactions in laboratory 
animals. Simonsen and Billingham first described a syndrome of spleno¬ 
megaly, hepatomegaly, thymic hyperplasia and runting (first called the 
"runting syndrome" then renamed the GVH reaction) when adult allogeneic 
33 
spleen cells were injected into neonatal mice. The donor cell reactions 
only occurred if the recipients were first rendered tolerant. The pro¬ 
cedures necessary to induce tolerance also limited the ability of in¬ 
vestigators to study the donor-recipient cell interactions. In 1962, 
Simonsen presented a new animal model system for studying the GVH reaction 
In this system, two strains, each homozygous at the H2 histocompatibility 
loci, are crossed such that the has one set of loci from each parent. 
The Fy is tolerant to both parents’ cells while each parent can recognize 
the H2 antigen of the other present in the F-^ and mount a reaction 
against it. In this system, the F-^ does not have to be immunologically 
depleted in order to establish a unidirectional reaction of the donor 
cells rejecting the host. 
Early investigations demonstrated that the GVH reaction followed 
the lines of a classic immune reaction. If the donor was made tolerant 
to the recipient’s antigens prior to injection, the GVH reaction could be 
35 




If the donor was immunized with the host’s cells prior to injection, 
the reaction could be magnified.^ ^ Billingham and Silver demonstrated 
that the small lymphocyte in the peripheral blood could cause the GVH 
O O 
reaction. When Davies and Doak showed that cells from neonatally 
thymectomized animals could not cause the GVH reaction, the role of 
the thymus in cellular immune reactions was established and the GVH 
system became a prime model for further investigation. Elkins 
showed that the kidney in the GVH reaction had the same pathological 
40 
picture as the kidney in allograft rejection. He also demonstrated 
that the donor cells were specifically activated by the H2 antigenic 
difference of the host. 
More recently, investigators have shown that some type of cellular 
interactions occur between subpopulations of donor cells in the GVH 
reaction. Cantor and Asofsky have demonstrated that different sources 
41 
of mouse lymphoid tissue could act synergistically in the GVH reaction. 
In these experiments, all the cells which could act synergistically 
had to be specifically reactive against the host cells. Work pub¬ 
lished concurrently by Hilgaard and Gershon and Barchilon have demon¬ 
strated synergism between combinations of parental T cells and parental 
and Fy bone marrow derived cells (BMD cells).5 ^ In these experi¬ 
ments, synergy occurred between specifically activated immune cells 
(the T cell) and non-specific, nonimmune BMD cells. Liebhaber has 
suggested that these results may not be contradictory. He postulated 
— 
6 
a three cell interaction involving two subpopulations of T cells, each 
specifically activated, which synergize and then affect non-specific 
BMD cells.42 
A different line of evidence supports the concept of cooperation 
between T cells and other immunologically active cells. Clamaan measured 
the hemolysin response to sheep RBC in lethally irradiated mice after 
AO 
injecting various combinations of T cells and B cells. In these 
experiments, either B cells mixed with T cells or spleen cells mixed 
with T cells gave a significantly greater response than the sum of the 
individual responses. Davies and his colleagues showed that the T cell 
did not produce antibody, but it greatly increased the ability of B cells 
to do so.44 Several investigators have shown that the immunologic speci¬ 
ficity in these cellular interactions rests with the B cell.4^-4^ Other 
workers have shown that in those systems which involve T cells in anti- 
48 
body production, tolerance rests with the T cell. 
Cooperation between T cells and BMD cells occurs in other immune 
49 
responses, as the mouse foot pad response to methylated serum albumin. 
In this experiment, the investigators demonstrated that the T cell was 
the immunologically specific cell while the BMD cell was a non-specific 
effector cell. Other investigators have confirmed this relationship 
in different animal model systems.The BMD cell involved in 
these reactions is probably not the antibody producing B cell. Recent 
evidence suggests that the macrophage is playing the role of the non- 
ro 
specific effector cell in these cellular mediated immune reactions. 
£' 
7 
The complex interactions involving T cells outlined in the pre- 
ceeding pages may actually represent the actions of more than one T 
cell population. Re if and Allen were among the first to note that 
53 
the T cell membrane carried an antigenic marker, the theta antigen. 
Other investigators have shown that the theta antigen is specific for 
54 
lymphocytes which have passed through the thymus. Specific anti¬ 
theta antibody and compliment can lyse cells carrying the antigen. 
Another antigenic marker, the T1 antigen, was found among the cells 
55 
from the thymic cortex. The thymus cells of the medulla and cortex 
can also be separated by their sensitivity to cortisone. Dougherty 
noted that animals treated with corticosteroids lost nearly all the 
cells in the thymic cortex while the cells in the medulla appeared to 
be unaffected (the medullary thymocytes have been named cortisone- 
resistant thymus cells).56 The T1 antigen is specific for those cells 
57 
which are sensitive to cortisone. 
Several lines of investigation have demonstrated that the cortisone- 
resistant T cells are immunologically much more active than the cortical 
thymocytes. Warner has shown that the cortisone-resistant T cell is 
much more active than whole thymus cells in damaging the chick chorio¬ 
allantoic membrane.The phytohemagglutinin responding cells in the 
pig thymus were shown to be cortisone resistant.59 Blomgren and 
Andersson have done a series of experiments in which the cortisone- 
resistant cell was shown to be ten times more effective per cell than 
whole thymus cells in inducing splenomegaly in the GVH reaction and in 
. 
The experiments interactions of B cells to T dependent antigens, 
which have separated these two thymus cell populations indicate that 
the cortisone-resistant T cell is a highly immunocompetent cell in¬ 
volved in all the previously described T cell reactions. The role of 
the cortisone-sensitive cell, which comprises ninety-five per cent 
of the thymocyte population,has remained an enigma until recent in¬ 
vestigations by Gershon's group. They have shown that the cortisone- 
sensitive cell can stimulate or suppress the response of the cortisone- 
resistant T cells as measured by the DNA synthesis of spleen cells in 
the GVH reaction.^ 
Pharmacologic doses of cortisone could produce an artifactual 
division inlhe thymus population, though this seems unlikely in the 
presence of such diverse experimental observations supporting separation 
of the populations both antigenically and functionally. 
Another line of evidence also suggests the presence of subpopula¬ 
tions of T cells with regulator and effector functions. Lance and Taub 
noted that anti-lymphocyte serum (ALS) in low doses specifically eli¬ 
minated a population of T cells which were recirculating, or found in 
lymph nodes, but did not affect T cells in the spleen or thymus. 
Several investigators have shown that decreasing the number of recir¬ 
culating T cells of the host greatly decreases the GVH activity. ^5-o(j 
Asofsky’s group has recently done a series of experiments in which 
cells from the peripheral blood and cells from the thymus and spleen 








two cell populations, each immunologically specific, acted synergistically. 
Both cell populations were composed of T cells, as discussed previously.^ 
They have demonstrated that the population of cells located in the 
thymus and spleen, which are resistant to low doses of ALS, are the 
precursors of the cell which "inflicts immunologic injury." The T2 
cell found in the blood and peripheral lymph nodes, which is very sen¬ 
sitive to low doses of ALS, acts to amplify the activity of the Tj_ 
cell. As described previously, many investigators have shown that 
T cells can act as "helper cells" to increase the antibody production 
of B cells. Recently Miller’s group has demonstrated that ALS in low 
doses can destroy the T helper cells as measured by the B cell response 
to certain antigens.^9 These results are particularly important as 
they suggest that humoral and cellular mediated immune responses may 
be under the control of a single cell population, the T2 cell. 
There is no evidence that relates the Ty and T2 populations to 
cortisone-sensitive and resistant T cells. These groups of T cells 
seem to be related functionally, but any conclusions must await further 
investigations. Clearly subpopulations of T cells which have different 
functions exist. Experiments have been discussed which demonstrate 
that T cells can amplify both humoral and cellular mediated responses. 
A body of evidence is now accumulating which indicates that T cells 
also can suppress the immune response. 
Several investigators have demonstrated that an animal tolerant 
70-71 





McCullagh has shown that allogeneic T cells injected into a rat tolerant 
to an antigen permits the animal to respond, while syngeneic T cells 
have no effect. Work by Gershon's group indicates that the T cell 
is required for both the induction of tolerance and immunity for in¬ 
dependent antigens (Antigens for which T cells act as helper cells to 
no 
boost antibody production). ° They have also demonstrated that anti¬ 
genic competition, the phenomenon in which an immune response induced 
to one antigen may inhibit the response to another unrelated antigen, 
is also dependent on T cells. Recently Tada and his associates 
have presented evidence that the suppressor effects of T cells are 
immunologically specific. The antibody to a haptene conjugated 
to one carrier was suppressed by the addition of T cells from a syn¬ 
geneic animal hyperimmunized against the haptene-carrier combination, 
but antibody to the haptene conjugated to a different carrier was un¬ 
affected. Baker and his colleagues have published a series of papers 
concerning the antibody response to pneumococcal polysaccharide type 
1 A 
III (S III), another antigen described as T cell independent. They 
have shown that the administration of low doses of ALS causes an increase 
in the antibody against S III due to an increase in antibody producing 
77 
cells. They suggested that this increase was due to the elimination 
7 8 
of a suppressor T cell. 
In the past, different workers have noted that splenectomized 
animals can elicit a greater immune response against a tumor graft than 
whole animals. In light of the localization of the T-^ cell to the 
') 
11 
spleen,some investigators have reinterpreted this data to be another 
example of T cell suppression. Field has presented evidence that F]_ 
rats become refractory to the induction of a GVH reaction after having 
had a GVH reaction previously. Field suggested that a humoral factor 
80 
mediated this suppressed immunologic state. Recently Michael and 
Veit have demonstrated an inhibitory factor present in the serum of 
mice which specifically suppresses the response of T cells to T-dependent 
antigens. Though no one has yet shown that T cells produce a suppre¬ 
ssor substance, the evidence indicates that either the T cell itself 
produces such a substance or it is associated with another unidentified 
cell which does. 
Thus the experiments on T cell suppression include both humoral 
and cellular mediated immune responses, like the data on T cell ampli¬ 
fication. It is particularly noteworthy that the data regarding the 
effect of low doses of ALS on antibody production by Baker suggests 
that the T2 cell, which Asofsky has described as an amplifier cell, 
also has suppressor function. This could be explained by either the 
presence of other subgroups with opposite effects within the T2 group, 
or by the hypothesis that the T2 cell effects the regulation of an 
immune response according to the antigen and the circumstances surround¬ 
ing the stimulus, as Gershon has suggested.^ 
Much of the evidence for the thymus cell reactions discussed have 
come from studying antibody production or the GVH reaction. Many 




cellular immune reactions. Some of these systems employ various com¬ 
binations of cells and sera to kill allogeneic or xenogeneic cells. 
The endpoint measured frequently is the release of some labeled particle 
which has been incorporated in the target cell. Several different 
lines of investigation have been pursued, each demonstrating a different 
cellular interaction necessary to kill a target cell. 
Lonai and Feldman have used a system involving rat donor cells 
and mouse fibroblasts as the target cell to demonstrate that T and 
84 
BMD cells act synergistically to lyse target cells. They have pre¬ 
sented evidence that the T cell is the immunologically specific cell 
in this system.^ Alexander’s group, working in an allogeneic in 
vitro system, have shown that T cells themselves have little cyto¬ 
toxicity. In this system the T cells produce a factor that induces 
cytotoxic cells from the bone marrow.^ MacLennan has experimental 
evidence along a similar line that demonstrates that the effector cell 
87 — 88 
is triggered by an IgG complexed with a target cell antigen. 
Other investigators have shown that the macrophage is involved in 
lysing allogeneic cells. Granger and Weiser were among the first to 
show that macrophages lyse cells by intimate cell contact, not by 
89 
phagocytosis. Evans and Alexander have shown that macrophages are 
immuno logic ally specific effector cells. They have demonstrated 
that media from spleen cells immunized against a specific target cell 
contains a factor, "macrophage arming factor," which renders macrophages 
no 
specifically cytotoxic for the target cells. 
. 
13 
Other investigators have used different cell populations from 
spleens and lymph nodes to demonstrate that the immunized effector cells 
do not release a toxin.9o-9^ Moreover, if one removes the macrophage 
from immunized peritoneal exudate cells, target cell lysis is unaffected.95-1,5 
Brunner, Nordin, and Gerottini have done a series of experiments to 
help clarify the confusing array of data in this area. They have 
shown that spleen cells from mice immunized with alloantigens contain 
immune lymphocytes and alloantibody-producing cells (PFC).' If this 
heterogeneous population is treated with anti-theta and compliment 
no in vitro target cell lysis occurs, but the number of PFC is unaffected.9®-99 
When they treated peritoneal cells from mice immunized against allogeneic 
cells with anti-theta serum and compliment, cytotoxicity was abolished. 
But when these cells were treated with anti-macrophage serum and compli¬ 
ment no effect was noted on target cell lysis in vitro. 
The function of cells in vitro and in vivo may not necessarily 
be the same. Freedman, Cerottini, and Brunner therefore examined 
these same questions in a functional in vivo animal model which they 
developed. They showed that allogeneic tumor cells were rejected 
by immune specific spleen cells which were derived from T cells. They 
could not demonstrate the presence of any mediators involved in the 
actions of the immune T cells. Moreover, the T cells acted independently 




Miller and his colleagues were among the first to demonstrate 
that the thymus gland played a central role in the development of peri¬ 
pheral lymphoid tissue and was essential for the function of the immune 
system. 102-103 ^he Specific role of the T cell in the body’s defense 
is slowly being delineated. When Davies established that cells from 
a thymectomized animal could not cause a GVH reaction, it became 
clear that the T cell was a principle participant in cellular mediated 
immune responses. Several different types of experimental studies 
have shown that subpopulations of T cells with different functions 
exist. 
Asofsky and Cantor have presented experiments in which cells, 
which are insensitive to low doses of ALS and are located in the thymus 
and spleen, effect immunologic injury, while the T2 cell, which rapidly 
recirculates and is very sensitive to low doses of ALS, can amplify 
the effect of the cell. Gershon's group have also demonstrated 
that one subpopulation of T cells, the cortisone sensitive cells, can 
regulate the effect of a second T cell population, the cortisone-resis- 
, , 106 
tant cells. 
Interactions also occur between T and B cells in which the T cell 
acts to suppress or amplify the antibody producing B cells.07-108 
Investigators have also shown that T cells interact with T cells as 
well as with BMD cells (which are probably macrophage) in cellular 
V. 
15 
immune reactions. -*-09-110 Thus it is clear that the T cell not only 
plays a major role in effecting immunologic injury in cellular mediated 
immune responses, it also is involved in regulating the T cell injury 




Freedman, Cerottini, and Brunner have demonstrated that in vivo 
the T-derived sensitized cell is able, by itself, to bring about the 
rejection of allogeneic tumor cells. This reaction does not require 
antibody, B cells, or macrophages and cannot be accomplished by anti¬ 
body producing B cells and macrophages in the absence of specifically 
sensitized T-derived lymphocytes. In this system C3H(H2K) thymus 
cells were sensitized to H2 antigens by injection into lethally irradi¬ 
ated (850 rads) allogeneic hosts, the DBA2(H2D), thus establishing a 
GVH reaction. The sensitized T cells were then harvested from the 
allogeneic hosts’ spleens and injected into C3H(H2K) recipients at the 
same time as ascites tumor cells (P-815-X2) carrying the same H2 
antigen as the DBi^I^D) (see figure I). The investigators showed 
that the ascites tumor cell growth during the first four days after 
injection into the allogeneic host was the same as in the syngeneic 
host unless sensitized T cells were also added. Thus, this system 
allowed the investigators to examine the effects of sensitized T cells 
on allogeneic tumor cell growth in a syngeneic animal. 
In this thesis the same animal model was used to determine whether 
T cell interactions also occurred in tumor allograft rejection as has 
112 
been described in other cellular mediated reactions. The animal 
model developed by Freedman et al allows one to examine modifiers of 
• > l 
'■ ' ’ , 
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T cell activity in both the afferent limb of the immune response, or the 
stage when sensitized T cells are formed, and the efferent limb, or 
the stage when the sensitized T cells effect tumor killing. In the present 
experiments, the afferent limb was investigated by examining the relation¬ 
ship between the dose of thymus cells required to produce sensitized 
T cells and the degree of tumor suppression. A similar series of 
experiments were undertaken to evaluate the efferent limb by examining 
the relationship between the dose of sensitized T cells and the degree 
of tumor suppression. To see whether subpopulations of T cells exerted 
a regulatory influence upon each other, cortisone-resistant cells were 
compared to whole thymus cell populations as to their effect on tumor 
growth. Experiments were also done to determine whether the syngeneic 





Materials and Methods 
Mice: All mice were males from Jackson Laboratory, Bar Harbor, Maine. 
C3H thymocyte donors were five weeks old. CDF^ and C3H recipients 
were seven or eight weeks old. All mice were rested one week in the 
laboratory before use. 
Irradiation: Recipient mice received 850 rads (mid-axial dose) from 
a Siemens Stabillipan 250 kv machine (Siemens Corporation, Iselin, 
New Jersey) with a two millimeter aluminum filter at a rate of 85 rads 
per minute. 
Cell Suspensions: Donor animals were sacrificed by exsanguination and 
the thymus and spleen were then removed, taking care to avoid any proxi¬ 
mal lymph nodes. The organs were ground in tissue grinders. The sus¬ 
pensions were treated with 2000 units of streptokinase and 500 units 
of streptodornase per 40 cc. of suspension. The suspension was allowed 
to settle for twenty minutes at room temperature, after which the super¬ 
natant was decanted and then spun at 1500 RPM for ten minutes. The cell 
button was washed and respun twice at 1500 RPM for five minutes. Medium 
199 with ten units of heparin per cc. was used for resuspension. Viable 
cells were counted at the final dilution using the trypan blue dye 
exclusion method. Thymus cell suspensions were injected intravenously 
at a dose of .2 to .5 cc. (within each experiment the dose was constant). 
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Tumor Cells: Cells syngeneic with the mouse (P-815-X2 
mastocytoma cells) were maintained by serial in vivo passage accord- 
ing to previously described methods. Tumor cells were obtained by 
peritoneal lavage of the passage animals. The cells were spun at 
1500 RPM for five minutes, then resuspended in medium 199. Viable 
cells were counted using the trypan blue dye occlusion method. All 
injections were made intraperitoneally with 3 x 10^ cells diluted to 
.5 cc. 
Enumeration of tumor cells in the peritoneal cavity: Following the 
method described by Freedman et al, the mice were anesthetized with 
114 
ether, then killed by cervical dislocation. The peritoneal cavity 
was exposed, then injected with 5 cc. of medium 199 with ten units of 
heparin per cc. The peritoneum was vigorously massaged and then aspirated. 
The peritoneum was slit open so that any remaining fluid could be drawn 
up. Cells were spun at 1500 RPM for five minutes then resuspended at 
appropriate dilutions for counting. Viable cells were determined using 
the trypan blue dye exclusion method. In the animals not treated with 
immune T cells, tumor cells were easily distinguished from other peri¬ 
toneal cells. When the animals were treated with the sensitized T cells, 
the tumor cells were more difficult to distinguish from other cells. 
Initially tumor cell counts were compared to counts made from Wright 
stain smears with good correlations. 
Experimental Design: Sensitized T cells were prepared by injecting 
intravenously C3H(H2K) thymus cells at different doses into lethally 
r 
20 
irradiated (850 rads) CDF^ according to the protocol in each experimental 
section. Five days post injection, the CDF^ were sacrificed and the 
spleens harvested. All nucleated cells from each spleen were counted 
by the trypan blue dye exclusion method. Usually 3-15 x 10^ cells were 
present in one spleen. The number of cells recovered from a spleen bore 
no relation to the thymus cell dose used to prepare the sensitized cells. 
There also was no correlation between the number of cells in a spleen 
and the eventual degree of tumor suppression. The spleens from each 
thymus cell dose were prepared such that the sensitized T cells from 
one spleen were diluted in 1 cc. of medium 199 with ten units of heparin 
per cc. In experimental sections III, IV and V the sensitized T cells 
were diluted according to the protocol in each section such that half, 
one-quarter, or one-eighti the cells from one spleen were diluted in 
1 cc. of medium 199. All test suspensions of sensitized T cells were 
z: 
injected intraperitoneally at the same time as 3 x 10° P-815-X2 masto¬ 
cytoma cells (diluted to a standard volume of .55) into seven or eight 
week old C3H(H2K) mice. In experimental section V, the C3H(H2K) reci¬ 
pients either received 850 rads two hours prior to use or received no 
irradiation according to the protocol. All tumor cell recipients were 
sacrificed four days after injection and the tumor cells in the peri¬ 




Section I Growth of Ascites Tumor Cells in Allogeneic and Syngeneic 
Recipients 
Preliminary tests confirmed the results of Freedman et al that 
P-815-X2 mastocytoma cell growth was not different for the first four 
days after injection into C3H(H2K), DBi^C^D), or CDF-^ normal or 
lethally irradiated ( 850 rads) recipients.j^g numt,er of tumor 
cells recovered four days after the injection of 3 x 10^ cells was 
O 
always in the range of 1 x 10 cells. Thus it was possible to examine 
the effect of syngeneic sensitized T cells on allogeneic tumor cell 
growth. 
Section II. The Effect of the Number of T Derived Lymphocytes used 
for Sensitization on Tumor Cell Growth 
Different doses of C3H(H2K) thymus cells were used to produce 
sensitized T cells. The sensitized T cells from the CDF]^ hosts given 
different numbers of thymus cells were examined for their ability to 
suppress the growth of the allogeneic tumor cells in the non-irradiated 
C3H(H2K) host. Groups of five or six lethally irradiated CDF^ received 
C3H thymus cells in the following doses: 4 x 10^, 15 x 10^, 60 x 10^, 
and 120 x 106. On day five, the spleen cells harvested from each CDF^ 
were injected intraperitoneally at the same time as 3 x 10^ tumor cells 
into C3H recipients such that four to six animals each received the 
.0 l € 
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cells from one spleen at each thymus cell dose. Four days after the 
tumor cell injection, the recipients were sacrificed and the tumor cells 
in each mouse were counted. In figure 2 the number of cells counted in 
the test mice are expressed as the percentage of cells present in untreated 
CgH controls. The data in figure 2 represent a minimum of six different 
experiments involving at least 25 mice at each dose except 4 x 10^ 
which is represented by the mean number of tumor cells from 5 mice. 
Control cells included C3H T cells injected into lethally irradiated 
C3H mice. The spleens from this group were harvested and injected 
with 3 x 1()6 tumor cells into C3H recipients. Tumor growth was un¬ 
affected by these spleen cells. When untreated irradiated CDFy spleen 
cells were used tumor growth was also unaffected. These controls were 
each done on two occasions. 
If each thymus cell used for sensitization acted independently 
to effect tumor cell rejection, one would expect that doubling the 
thymus cell dose would roughly halve the number of tumor cells re¬ 
maining in the host. The data in figure 2 show that no significant 
difference was present in the number of tumor cells recovered when 
the thymus cell dose was increased from 15 x 10^ to 30 x 10^ or when 
it was increased from 60 x 10^ to 120 x 10^. An eight fold increase 
in the thymus cell dose from 15 x 10^ to 120 x 106 increased tumor 
suppression roughly three fold. The data indicate that the growth 
of tumor cells is related to the number of thymus cells used to prepare 
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the sensitized T cells, but not in a linear fashion. These findings 
suggest that some type of regulation occurred which either suppressed 
or amplified the effects of the sensitized T cells. 
Section III. The Effect of the Number of Sensitized T Derived Lymphocytes 
on Tumor Cell Growth 
The following series of experiments were designed to evaluate 
whether tumor suppression was related in a one-to-one fashion to the 
number of sensitized T cells used in vivo as has previously been 
shown by Brunner et al in vitro. Thus different numbers of sensi¬ 
tized T cells from the spleens of mice given individual doses of thymus 
cells were used to determine their effect on allogeneic tumor cell 
rejection. 
Groups of lethally irradiated CDF-^ were injected intravenously 
with C3H thymus cells at four doses: 15 x 106, 30 x 10^, 60 x 10^, 
and 120 x 106 as in section II. The spleen cells were harvested on 
day five and injected intraperitoneally at the same time with 3 x 10^ 
tumor cells such that each recipient received all the cells from one 
spleen, or one-half the cells, or one-quarter the cells, or one-eighth 
the cells from the CDF^ which had been injected with 120 x 10^ thymus 
cells. Four to six C3H recipients were in each experimental group. 
The same protocol was followed with the sensitized T cells prepared 
from the thymus cell doses of 15 x 10^, 30 x 10^, and 60 x 10^. Each 
C3H recipient was sacrificed four days after injection and the tumor 
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cells were counted. The cells counted were expressed as a percentage 
of the cells present in untreated controls. Each number in table 1 re¬ 
presents the mean from at least three experiments each including four 
to six mice. Clearly the sensitized T cells prepared at any of the 
thymus cell doses are not related in a linear fashion to the suppression 
of tumor cell growth. Doubling or quadrupling the absolute number of 
sensitized T cells prepared from the 15 x 10^ or 30 x 10^ thymus cell 
dose had no significant effect on the degree of tumor cell growth. 
The data indicate that the sensitized T cells must be influenced by other 
factors (cellular or humoral) in effecting immunologic injury. 
Section IV. The Effect of Cortisone Sensitive Cells 
The previous experiments demonstrated that the thymus cell dose 
used co prepare the sensitized T cells was not related in a one-to-one 
fashion to tumor kill. Also it was shown that this deviation from a 
linear relationship occurred in the efferent limb of the tumor rejection 
response, though the possibility that regulation occurred in the sen¬ 
sitization limb was not ruled out. The next question asked was whether 
subpopulations of T cells might be interacting and thus regulating the 
degree of immunologic injury. Gershon has shown that cortisone sensitive 
T cells were able to regulate the level of T cell DNA synthesis in the 
spleens of mice undergoing a GVH reaction.In the following experi¬ 
ments the roles of cortisone sensitive and resistant T cells were evalu¬ 
ated in tumor allograft rejection. 
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Thymus cell donor mice were treated with 2.5 mg. of cortisone 
acetate ("Contone," from Merck, Sharpe, and Dome) 48 hours prior to 
the harvest of thymus cells. These cells were prepared in the same 
fashion as whole thymus cells and were counted using the trypan blue 
dye exclusion method. Each thymus yielded 2 1/2 to 5% the number of 
cells from the thymus of untreated animals. As the normal role of 
cortisone sensitive cells was in question, not the per cell effective¬ 
ness of cortisone sensitive cells versus resistant cells, the number 
of cortisone resistant cells expected in a whole thymus cell yield was 
considered "equivalent" to a whole thymus. If the yield from an average 
untreated thymus was 120 x 10^, the yield from the average cortisone 
treated thymus was considered "equivalent" to 120 x 10^ cells. Thus 
in a particular experiment in which thirty mice were to be used as 
thymus cell donors, fifteen were pretreated with cortisone. The two 
groups of thymuses were harvested and prepared in exactly the same 
manner. The final dilution was attained at which the desired number of 
whole thymus cells were suspended in .3 cc of medium. The cells pretreated 
with cortisone were diluted to the same level. Thus both groups of cell 
suspensions should have had the same number of cortisone resistant 
cells, but the whole thymus cell preparation had, in addition, cortisone 
sensitive cells in the same proportion as found in the thymus gland. 
Groups of five or six irradiated CDF^ were given whole thymus cell 
doses of 15 x 10^, 30 x 10^ or 60 x 10^. Other groups of five or six 





30 x 106, or 60 x 106 cells. On day five the CDF-^ spleen cells were 
harvested. Each C3H recipient received 3 x 106 tumor cells injected at 
the same time as either the cells from one spleen, one-half spleen, or 
one-quarter spleen at the different doses of normal and cortisone 
equivalent T cells. Four days after injection the C3H were harvested 
and the tumor cells were counted. The cells were expressed as the per¬ 
centage of cells in C3H controls. One such experiment is presented in 
Table 2. At the high dose the cortisone equivalent cells were five times 
as effective in suppressing tumor growth as whole thymus cells. At 
the low dose the cortisone resistant cells were only one-tenth as 
effective as whole thymus cells. In Table 3 the results from four 
experiments are summarized. Each number represents the ratio of regular 
thymus cells to cortisone resistant cells of the mean of the counted 
cells from four to six animals expressed as the percentage of cells in 
C3H controls. (The data in Table 2 are the results from experiment 
three at one spleen and are present in Table 3 as a ratio of five and 
one-ninth.) Each experiment was done comparing a high dose (60 x 10^) 
of thymus cells to a cortisone equivalent dose and comparing a low dose 
(15 x lO^ or 30 x 10^) of cells to a cortisone equivalent dose. 
The data demonstrated that the cortisone sensitive cells in some 
manner regulated the immunologic injury effected by whole thymus cell 
preparations. The cortisone resistant cells from a high dose of cells 
used for sensitization were more effective suppressing tumor growth 
than the same absolute number of cortisone resistant cells in the 
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presence of cortisone sensitive cells. In this situation, the presence 
of the cortisone sensitive cells suppressed the effect of the sensitized 
T cells. At the low dose of cells used for sensitization, the presence 
of cortisone sensitive cells amplified the immunologic injury inflicted 
by the sensitized T cells. These experiments demonstrated that this re¬ 
gulation occurred at the efferent limb of the tumor rejection process. 
The results of the sensitized T cells from one spleen prepared from the 
high dose of thymus cells showed that the cortisone resistant cells 
were more effective when the cortisone sensitive cells were not present. 
When the absolute number of sensitized T cells was decreased by using the 
cells from one-half or one-quarter spleen, the presence of the cortisone 
sensitive cells increased the tumor killing. This is demonstrated in 
experiment two, Table 3, by the change in ratio from 18 when the cells 
from one spleen were used to the ratio of 1/6 when one-quarter spleen 
cells were used. The data do not rule out the possibility that T cell 
interactions occurred during the sensitization process. It is important 
to note that when normal whole thymus cells were diluted to the same 
absolute numbers as the cortisone resistant cells (the thymus cell 
dose of 4 x 10^ used in section II, Figure 2, is the same number of cells 
as the cortisone equivalent dose to 60 x 10^ in Table 2) the cortisone 





Section V. The Effect of Irradiation of the Host on Tumor Killing 
by Sensitized T Cells 
In preceeding experiments cellular interactions were demonstrated 
between cortisone resistant and sensitive populations of T cells which 
lead to regulation of the sensitized T cells in the destruction of allo¬ 
geneic tumor cells. It was decided to investigate next whether the 
host’s cells might also be involved in interactions with sensitized 
T cells. The work of Freedman et al has isolated the T derived lympho- 
cyte as being capable of working independently. However, all their 
experiments were done in heavily irradiated CgH recipients (850 rads) 
given large numbers of sensitized T cells (in terms of the present ex¬ 
periments the number of cells would be equivalent to the cells from 
two or three spleens). A dose of 50 x 10 ^ thymus cells were used to 
prepare the sensitized T cells. This high cell dose suppressed tumor 
growth completely and might well have obscured any regulatory effect 
mediated by the host. The irradiation of the test recipients would be 
sufficient to kill all the host cells usually involved in immunologic 
processes except the macrophages. 
To examine the possible role of host cells, sensitized T cells 
were prepared in the usual manner and were then injected with 3 x 10 
tumor cells in either normal C3H recipients or CgH recipients which had 
received 850 rads two hours prior to injection. Three experiments 
were done using only a high thymus cell dose (60 x 10^ or greater) 
and three experiments were done with both a high (60 x 10^ or greater) 
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and a low thymus cell dose (15 x 10^ or 30 x 10^). One such experiment 
is presented in Table 4. The degree of tumor killing in the normal 
C3H recipients at the high and low dose was the same, a result consistent 
with the dose response curve reported earlier in this study. In the 
irradiated recipients the high cell dose was significantly more effective 
suppressing tumor growth, while at the low dose the cells were signi¬ 
ficantly less effective. The data from six experiments are summarized 
in Table 5. The results are presented as the ratio between normal and 
irradiated recipients of the mean number of tumor cells counted, expressed 
as the percentage of cells present in C^H controls. Thus the data from 
Table 4 are expressed as a ratio of 1/5 at the low dose and a ratio of 
4 at the high dose in Table 5. These results demonstrated that the host 
did interact with the syngeneic sensitized T cells and that this inter¬ 
action was part of the regulation of the sensitized T cell effect. 
Irradiation most likely eliminated a radiosensitive cell which was in¬ 
volved in suppressing and amplifying the immune response against the 




These experiments were designed to evaluate the possibility that 
T cell activity in a tumor allograft rejection system was subject to 
regulation. The results indicated that regulatory mechanisms do exist, 
that they are demonstrable between subpopulations of T cells in the 
effector limb of the rejection process, and that one of the mechanisms 
involves a radiosensitive host cell. 
Studies were undertaken to determine whether the relationship 
between the dose of thymus cells and the degree of tumor suppression was 
a first order reaction. In enzyme kinetic studies, the investigator 
can measure the amount of each reactant and the final product, and 
then draw conclusions regarding the product as a function of the amount 
of reactants and the interactions between them. The results can be inter¬ 
preted to show whether the reaction is zero order, in which the product 
is independent of any variable; first order, in which the product is 
formed in a linear relationship to one reactant; second order, in which 
the product is a function of two reactants and is proportional to the 
square of the varied reactant; or order, in which the product is a 
function of N reactants and is proportional to the varied reactant 
raised to the power. In the experiments presented in section II, 
the number of tumor cells was kept constant while the dose of thymus 
cells used to prepare the sensitized T cells was varied. If a first 
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order reaction was present,doubling the number of thymus cells should 
have doubled the degree of tumor suppression. This did not occur, 
though it was clear from the dose response curve in figure 2 that the 
thymus cell doses used were not at either extreme of the curve where 
such a relationship might not be evident. Taub and colleagues have 
shown that the localization of T cells to mice spleens increased pro¬ 
portionally as the cell dose was increased (from 10^ to 10^).^^ Thus 
the results of these experiments are not due to variable homing of the 
different doses of thymus cells. Moreover, previous investigators have 
shown that lethally irradiated mice can be reconstituted with increasing 
doses of thymocytes (in the same dose range as these experiments) with a 
119 
result of an increasing DNA synthetic response to an antigenic stimulus. 
The mice spleens thus do have the room for these doses of thymus cells 
to react immunologically. The results in Table 4 also indicated that 
the same dose of thymus cells is capable of a greater immunologic response 
if a regulator influence is eliminated. Thus the curve in Figure 2 can 
be interpreted as indicating a suppressed order reaction in which an 
unknown number of cells are involved in regulating the immunologic 
response. 
Perhaps more to the point are the experiments from Section III 
in which a fourfold increase in the absolute number of sensitized T 
cells injected into the test animals did not significantly effect the 
degree of tumor suppression. Since only the sensitized T cells were 
being varied these experiments demonstrated that cellular interactions 
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occurred in the efferent limb of the tumor allograft rejection process. 
As in the preceeding experiments, this lack of a linear response to in¬ 
creasing doses of cells indicated that a suppressive interaction was 
occurring. These findings do not preclude the possibility that cellular 
interactions also occurred during the sensitization phase. Gershon's 
studies of the cell kinetics in the GVH reaction also demonstrated a 
suppressed order reaction, but the assay of the DNA synthesis of 
donor T cells in the F-^ spleen may reflect interactions during T cell 
. . . 120 
sensitization. 
The data concerning tumor cell killing in the irradiated host are 
particularly interesting. Though the degree of tumor suppression was 
unaffected by quadrupling the number of thymocytes delivered to the 
normal host, the same thymocytes delivered to an irradiated animal 
reacted quite differently (see Tables 4 and 5). At high doses the 
immune cells were much more effective suppressing tumor growth in the 
irradiated animals, and at low doses they were much less effective. 
Irradiation of the host appeared to eliminate a radiosensitive factor 
(cell) which was involved in suppressing or amplifying the action of 
immune T cells. 
These results may explain the "Celada effect". Celada noted that 
when presensitized syngeneic T cells were injected in a host, they did 
not produce antibody upon antigenic stimulus unless the host was lethally 
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irradiated. In these experiments, irradiation may have eliminated 
host cells which were suppressing the presensitized antibody producing cells. 
- • 
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In studies of cortisone sensitive and resistant T lymphocytes (Tables 
2 and 3) a similar type of regulation was demonstrated. When cortisone 
sensitive cells were eliminated, the cortisone resistant cells were more 
effective tumor killers at a high dose, and less effective at a low dose. 
These experiments showed that cortisone sensitive cells were involved 
in both suppressing and amplifying the effects of immune T cells. When 
the efferent limb of the tumor rejection process was isolated, the corti¬ 
sone sensitive cells were again shown to be suppressing or amplifying 
the effect of the sensitized T cells. These experiments do not indicate 
whether the regulatory effects of the cortisone sensitive cells were 
confined to the efferent limb of the tumor rejection reaction, or were 
also present in the afferent limb. If the absolute number of sensitized 
T cells harvested from the spleens were known, the effect of the 
cortisone sensitive cells during sensitization might be clear. All the 
nucleated cells harvested from the spleens were counted; however, 
there was no way of distinguishing the F^ host cells from the C3H T 
cells. Moreover, if these allogenic cells were separated by appropriate 
antiserum, there is no way presently of distinguishing which C3H T cells 
were sensitized and which were not. These experiments demonstrated that 
cortisone sensitive T cells were involved in a regulatory role and cor¬ 
roborate the evidence in sections II and III that T cell interactions 
occurred in the rejection of allogenic tumor cells. 
Davies and colleagues have shown that T cells can increase the 
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number of B cells producing antibody to certain antigens. Gershon’s 
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group has shown that T cells also can suppress antibody producing B 
cells.-*-23 The t cell thus appears to play a major role in the control 
of humoral immunity. The experiments presented in this thesis showed 
that T cells may also play a significant role in the control of tumor 
allograft rejection, and that a non-sensitized radiosensitive cell is 
probably involved in such controls. The regulation by the cortisone 
sensitive cell in the efferent limb of the tumor allograft rejection 
process is quite similar to the role played by the radiosensitive host 
cell, in that both are involved in amplifying and suppressing the effects 
of sensitized T cells. The data do not permit any conclusions that these 
processes are related. But one can hypothesize that the cortisone 
sensitive cell modifies the action of the sensitized T cells by inter¬ 
acting with a radiosensitive cell. This hypothesis is consistent with 
the findings of investigators that subpopulations of T cells and BMD 
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cells synergize in the GVH reaction. This type of model might 
be analogous to feedback inhibition systems demonstrable in enzyme re¬ 
actions and other biological processes. Such a system merges the differ¬ 
ences apparent in cellular and humoral immunity. It would be fascinating 
to know whether the T cells which regulate the B cell antibody response 
are cortisone sensitive. If this were the case, the whole array of 
immune responses might well be under the regulation of a population of 










Day I: Thymus ceils harvested from C3H (H2K) are injected in- , 
travenously into iethally irradiated CDF| (in Freedman's 
system, into D8A9 (H2D)). 
Day 5: Spleens harvested from CDF are injected with P-815-X2 
mastocytoma cells from passage animal into C3H (K2K) 
(in experimental section 5 half the test recipients were 
irradiated). 
Day 9: The tumor cells in each test animal are counted. 
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FIGURE 2 The Relationship of Thymus Ceil Dose 
to Tumor Suppression 
80 i 8.9 
Each number represents a minimum of , 
six experiments involving at least 25 mice g 
at each dose except 4x!0 which represents 
the resuits of 5 mice. Each number is the 
mean tumor cells counted expressed as the 
percentage of cells present in untreated 
C^H controls. 
P value comparing 120 Gnd 60 to 30 and 
15 less than 0.01 
P value comparing 120 or 60 to 30 or 
' 15 less than 0.01 
28.9 i 6.6 
„ 24 ± 4.9 
10.8 L 2.2 
13.8 A 2.2 
10 20 30 40 50 60 70 80 90 100 110 120 
Thymus Cell Dosage (x 10 j 
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TABLE I The Relationship of Sensitized T Cells 
to Tumor Suppression 
T Cell Dosage I Spleen 1/2 Spleen 1/4 Spleen 1/8 Spleen 
(x I06 ) 
120 
X 
13.8 sem 2.3 
X 
9.0 sem 3.9 X| 1.9 sem 5.7 30.5 sem 10 
60 
x 
10.8 sem 2.2 26 sem 8.3 24 sem 5.8 
30 24 sem 4.9 23.3 sem 5.3 24.9 sem 8.1 
15 29 sem 6.6 32 sem 9.1 
Each number represents the mean tumor cells 
counted from three experiments each including 
four to six mice expressed as the percentage of 
cells present in untreated C3H controls. 
Each starred value (x) is p less than 0.05 when 









2 The Effect of Cortisone Resistant T Ceils 
Compared to Cortisone Resistant and Sensitive 
T Cells 
Dosage of 
T Cells (x 10s) 
Mean SEM 
30 99 5.5 
30 92.6 7.3 
60 12.5 2.1 
60 2.6 0.49 
Each number represents the rn^an tumor cells from 
4 to 6 mice expressed cs the percentage of cells 
present in C^H controls. 
(a) p less than O.OI when whole thymus cells 
compared to cortisone equivalent doss for 
both dosages 
(b) when cortisone equivalent 30 compared to 
cortisone equivalent 60, p less than 0.001 





TABLE 3 The Relationship between Cortisone 
Resistant and Sensitive Cells as the 
Number of Sensitized Cells is Decreased 
c c 
Thymus dose: greater than 60 x 10^ less than 60 x 10 
Exper. no. I Spleen 1/2 Spleen 1/4 Spleen I Spleen 1/2 Spleen 
i 1 1/2 
2 18 6 1/6 1/3 2/3 
3 5 3 1/2 1/9 1 
4 4 1 1/2 1 
Numbers expressed as the ratio of the mean 
percentage tumor survival of cortisone sensitive 
and resistant cells compared to the mean per¬ 
centage tumor survival of cortisone resistant 
cells 
g 
I spleen and 1/2 spleen of greater than 60 x 10 
is different at the p less than 0.01 level from 
the less than 60x10^ I spleen and 1/2 spleen 
t test done on log values 
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TABLE 4 Tumor Growth Suppression in the 






T Cells (x 10s) 
Mean SEM 
120 2.3 0.45 
120 0.B6 0.27 
30 2.4 1.0 
30 11.4 2.3 
Each number represents the mean tumor cells from 
4 to 6 mice expressed as the percentage of cells 
in untreated C3H controls. 
e 
(a) Radiated recipients receiving 120x10 com¬ 
pared to 30 x10s were different to p less 
than 0.02 
(b) 120 x 10s is not significantly different from 
30 x I06 
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TABLE 5 The Effect of irradiation of the Test 
Animal on Sensitized T Cell Activity 
High Dose T Cells Low Dose T Cells 
Exper. no. ! Spleen 1/2 Spleen I Spleen 1/2 Spleen 
1 2 2/3 
2 1/5 1/3 




Each number is expressed as the ratio of 
the mean percentage survival from 4 to 6 
non-irradisted mice compared to the mean 
percentage tumor survival from 4 to 6 ir¬ 
radiated mice. 
The high dose effect is statistically dif¬ 
ferent from the low dose effect to p less 
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